Latest Imaging Solution From Amersham Biosciences Simplifies 2-D Gel Analysis

February 3, 2004 – Newly updated 2-D electrophoresis gel image analysis software available from Amersham Biosciences, the life sciences company of Amersham (LSE:, NYSE:, OSE: AHM), is to help address critical bottlenecks of image analysis in proteomics research.

The new spot detection and matching algorithms of ImageMasterâ„¢ 2D Platinum 5.0 facilitates the extraction of statistically valid differences between groups of 2-D gels reliably and efficiently, while requiring minimal user intervention and therefore speeding up analysis time. Integrated with LabScan 5.0, a newly developed 2-D gel scanning tool that enables seamless transfer of images to ImageMaster 2D Platinum 5.0, this 2-D image analysis suite manages the entire workflow from image acquisition to the discovery of biologically important proteins.

“This new version of ImageMaster will enable proteomics researchers to generate high quality biological data quickly and reliably,” said Richard Cumming, VP Product Management, Proteomics at Amersham Biosciences. “Researchers carrying out 2-D electrophoresis gel analysis can now directly validate significant results, rather than spending time on endless data extraction.”

ImageMaster 2D Platinum 5.0 is the second 2-D software product to be launched as a result of the alliance between Amersham Biosciences and Geneva Bioinformatics (GeneBio) S.A., and benefits from the proteomics application knowledge and software synergies of both companies. The incorporation of the renowned Melanie 2-D Gel analysis software developed by the Swiss Institute of Bioinformatics (SIB) as the new backbone of ImageMaster will offer researchers the next generation of proteomics image analysis software to further their proteomics research.

Amersham Biosciences, the life sciences business of Amersham (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences’ products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia.

Amersham Biosciences—enabling molecular medicine

Journalist Enquiries:
Amersham Biosciences: Helen Petts, PR Manager
North America: Eric Rayvid, Evins Communications
Europe: Matthew Kent, CPR Worldwide – +44 (0) 207 395 7133